 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The sentiment remains strong as long as it stays above 20,000 mark and also continued buy on dips strategy, say experts.

Top 10 stock ideas from experts when market trades at a fresh record high

Gufic Bio Standalone September 2023 Net Sales at Rs 214.87 crore, up 22.9% Y-o-Y

In a regulatory filing made after market hours yesterday, the company informed that it has been granted patent for an invention entitled “A freeze dried parenteral composition of Omadacycline Tosylate and process for preparation thereof” on September 14, 2023 for the term of 20 years effective from 19 April 2021 in accordance with the provisions of the Patents Act, 1970.Omadacycline is a new aminomethylcycline as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections.Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.The companys net profit had declined 2.04% to Rs 20.62 crore while net sales rose 17.99% to Rs 195.02 crore in Q1 June 2023 over Q1 June 2022.

Gufic Biosciences gains on grant of 20-year patent for antimicrobial Omadacycline  

Parecoxib Sodium Lyophilized Powder for injection, will be used for short-term treatment of acute pain and post-operative pain in adult patients. It is the first parenteral selective COX-2 inhibitor available for clinical use in pain management.Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of Active Pharmaceutical Ingredients (APIs). Gufic is a leading manufacturer of Lyophilized injections, boasting a fully automated lyophilization plant. Net profit of Gufic Biosciences declined 2.04% to Rs 20.62 crore while net sales rose 17.99% to Rs 195.02 crore in Q1 June 2023 over Q1 June 2022.

Gufic Bio rises on TGA, ANVISA nod for Parecoxib injection

&quot;The medicine will be used for short-term treatment of acute pain and post-operative pain in adult patients,” the company said in a regulatory filing at the exchanges.

Gufic Biosciences gains on Aussie, Brazilian nod to pain-killer drug

Gufic BioSciences has fixed 21 September 2023 as record date for final dividend payment for FY 2023. 

Gufic BioSciences fixes record date for final dividend 

Gufic BioSciences announced that the 39th Annual General Meeting (AGM) of the company will be held on 29 September 2023.

Gufic BioSciences to conduct AGM

The shares have a face value of Re 1 each and will be priced at Rs 300 per share, totaling Rs 99.99 crore. The relevant date for determining the issue price is 30 August 2023. Following the subscription, Motilal Oswal Financial Services will hold approximately 3.32% of the total shareholding post-preferential allotment. Prior to the allotment, Motilal Oswals shareholding was nil.Motilal Oswal Financial Services stated that the acquisition aligns with their long-term financial investment strategy as part of their Fund Based Investments approach.Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of Active Pharmaceutical Ingredients (APIs). Gufic is a leading manufacturer of Lyophilized injections, boasting a fully automated lyophilization plant. Its products cover various therapeutic areas such as antibiotics, antifungals, cardiac, infertility, antiviral, and proton-pump inhibitors. Gufic holds multiple regulatory approvals, including WHO-GMP, EU GMP, ANVISA Brazil, Russian GMP, Health Canada, Ukraine GMP, Australia TGA, Colombia INVIMA, and Uganda NDA. It has a production capacity of 48 million lyophilized vials annually.Net profit of Gufic Biosciences declined 2.04% to Rs 20.62 crore while net sales rose 17.99% to Rs 195.02 crore in Q1 June 2023 over Q1 June 2022. 

Gufic Bio jumps as Motilal Oswal to buy 3.32% stake

Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 1 September 2023.

Gufic BioSciences schedules board meeting

The share has touched a 52-week high of Rs 245.

Gufic Biosciences hits 52-week high China nod to anaesthesia API

Gufic Biosciences Ltd. engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. It operates through the following geographical segments: India, Africa, Asia, Europe, North America, Australia and South America. The company was founded on July 23, 1984 and is headquartered in Mumbai, India.

Market Cap	32.69B
Volume (M)	111,260.00
52-Wk High	348.25
52-Wk Low	177.65

GUFICBIO.NSE Gufic Biosciences Ltd.

About

Feed

News

Fundamentals